INmune Bio, Inc. (INMB) financial statements and ratios from SEC XBRL: revenue $50000.00 (TTM), net margin -91866.0%, revenue growth 257.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $50000.00 |
| Net Margin | -91866.0% |
| Revenue Growth (YoY) | 257.1% |
| EPS Growth (YoY) | -11.8% |
| Price / Book | 3.13 |
| Price / Sales | 389.23 |
| FCF Yield | -32.2% |
| Altman Z-Score | -8.93 (distress) |
| Sector P/E (Healthcare) | 21.7 |
INMB overview · INMB earnings · INMB KPIs · INMB investor relations · INMB ownership · INMB peers · INMB filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.